# Eisai Limited clinical trials: 48 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 48 trials with Eisai Limited as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Eisai Limited: 48 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/eisai-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 48
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 48, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 24, 2026 | NCT07781345 | A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD) | Eisai Limited | Observational | Not yet recruiting | Alzheimers Disease | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781345) |
| August 13, 2026 | NCT07762092 | A Post Authorization Registry Study of Participants Treated With LEQEMBI | Eisai Limited | Observational | Recruiting | Alzheimers Disease | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762092) |
| September 21, 2023 | NCT06043700 | A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology | Eisai Limited | Observational | Active not recruiting | Alzheimer's Disease | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06043700) |
| November 7, 2022 | NCT05607537 | A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in... | Eisai Limited | Phase 1 | Completed | Healthy Volunteers | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05607537) |
| April 12, 2021 | NCT04840927 | A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an... | Eisai Limited | Phase 1 | Withdrawn | Healthy Volunteers | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04840927) |
| July 30, 2020 | NCT04493255 | A Study to Determine the Metabolism and Elimination of \[14C\]E7090 in Healthy Male Participants | Eisai Limited | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04493255) |
| February 6, 2020 | NCT04257604 | A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures | Eisai Limited | Observational | Completed | Partial Seizures | 243 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04257604) |
| February 5, 2020 | NCT04252846 | A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants \>=12 Years With... | Eisai Limited | Observational | Completed | Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04252846) |
| December 23, 2016 | NCT03002493 | To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors | Eisai Limited | Phase 1 | Completed | Tumor | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03002493) |
| May 11, 2016 | NCT02769364 | Extended Treatment in Metastatic Breast Cancer With Eribulin | Eisai Limited | Observational | Completed | Breast Cancer | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02769364) |
| August 26, 2015 | NCT02533102 | Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers | Eisai Limited | Phase 1 | Completed | Healthy Subjects | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02533102) |
| May 13, 2015 | NCT02443428 | Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry | Eisai Limited | Observational | Completed | Breast Cancer | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02443428) |
| May 4, 2015 | NCT02432274 | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma | Eisai Limited | Phase 1/2 | Completed | Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC) | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02432274) |
| October 20, 2014 | NCT02268812 | Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the... | Eisai Limited | Observational | Completed | Pain Management, Severe Chronic Pain | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02268812) |
| November 25, 2013 | NCT01991041 | European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS) | Eisai Limited | Observational | Completed | Lennox-Gastaut Syndrome | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01991041) |
| September 18, 2013 | NCT01945710 | An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients... | Eisai Limited | Phase 1 | Completed | Solid Tumors | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01945710) |
| January 4, 2013 | NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment... | Eisai Limited | Phase 3 | Completed | Hepatocellular Carcinoma (HCC) | 954 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01761266) |
| June 13, 2012 | NCT01618136 | An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced... | Eisai Limited | Phase 1/2 | Completed | Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma, B-cell Malignancy, Low-grade | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01618136) |
| March 7, 2012 | NCT01546688 | A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With... | Eisai Limited | Phase 4 | Terminated | Epilepsy | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01546688) |
| February 13, 2012 | NCT01531920 | A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel | Eisai Limited | Phase 1 | Completed | Central Nervous System | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01531920) |
| July 27, 2011 | NCT01404169 | A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride... | Eisai Limited | Phase 3 | Completed | Alzheimer's Type Dementia | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01404169) |
| March 25, 2011 | NCT01323530 | A Confirmation Study of Eribulin in Combination With Capecitabine | Eisai Limited | Phase 1/2 | Completed | Metastatic Breast Cancer | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01323530) |
| December 31, 2010 | NCT01268527 | A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of... | Eisai Limited | Phase 2 | Completed | Psoriasis Vulgaris | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01268527) |
| July 29, 2010 | NCT01172379 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease... | Eisai Limited | Phase 2 | Completed | Parkinson's Disease | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01172379) |
| June 22, 2010 | NCT01146951 | A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304) | Eisai Limited | Phase 3 | Completed | Lennox-Gastaut Syndrome | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01146951) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 3 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 11 |
| Phase 4 | 5 |
| Observational | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |
| Terminated | 7 |
| Withdrawn | 1 |
| Suspended | 1 |
| Active not recruiting | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 7 |
| Epilepsy | 7 |
| Alzheimer Disease | 5 |
| Seizures | 5 |
| Parkinson Disease | 4 |
| Breast Neoplasms | 4 |
| Osteoporosis | 2 |
| Lennox Gastaut Syndrome | 2 |
| Colorectal Neoplasms | 2 |
| Cognitive Dysfunction | 2 |
| Carcinoma, Hepatocellular | 2 |
| Torticollis | 1 |
| Epilepsy, Idiopathic Generalized | 1 |
| Epilepsy, Tonic-Clonic | 1 |
| Obesity | 1 |
| Dementia | 1 |
| Delirium | 1 |
| Brain Diseases | 1 |
| Central Nervous System Diseases | 1 |
| Nervous System Diseases | 1 |
| Tauopathies | 1 |
| Neurodegenerative Diseases | 1 |
| Mental Disorders | 1 |
| Osteosarcoma | 1 |
| Carcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Live and raw food restaurants in the United States](https://specstream.ai/data/businesses/live-and-raw-food-restaurants/united-states)
- [IT consultants in the United States](https://specstream.ai/data/businesses/it-consultants/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
- [Health food restaurants in the United States](https://specstream.ai/data/businesses/health-food-restaurants/united-states)
